$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)

Core Viewpoint - Monteverde & Associates PC is investigating Day One Biopharmaceuticals, Inc. regarding its proposed sale to Servier Pharmaceuticals LLC, where shareholders are expected to receive $21.50 in cash per share, raising questions about the fairness of the deal [1]. Group 1 - The investigation is led by class action attorney Juan Monteverde, who has a successful track record in recovering millions for shareholders [1]. - The proposed transaction involves Day One shareholders receiving $21.50 per share, prompting scrutiny over whether this is a fair deal [1]. - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report, indicating its credibility in handling such cases [1].